Kah Poh Loh1, Janet A Tooze2, Barbara J Nicklas3, Stephen B Kritchevsky3, Jeff D Williamson3, Leslie R Ellis4, Bayard L Powell4, Timothy S Pardee4, Neha G Goyal5, Heidi D Klepin4. 1. Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, NY, United States. Electronic address: kahpoh_loh@urmc.rochester.edu. 2. Division of Public Health Sciences, Wake Forest Baptist Health, Winston-Salem, NC, United States. 3. Section Gerontology and Geriatric Medicine, Wake Forest Baptist Health, Winston-Salem, NC, United States. 4. Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, NC, United States. 5. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States.
Abstract
OBJECTIVES: To investigate changes in inflammatory biomarkers during induction therapy for older adults with acute myeloid leukemia (AML) and their associations with geriatric assessment (GA) measures and outcomes. METHODS: This was a single institution ancillary study to a prospective observational study (N = 20 consecutive adults aged ≥60 with newly diagnosed AML who received induction chemotherapy). Biomarkers (Interleukin-6 [IL-6], IL-6 soluble receptor [IL-6 sR], tumor necrosis factor alpha [TNFα], TNFα soluble receptor 1 [TNFα sR1], interleukin-3 [IL-3], C-reactive protein [CRP]) were collected at start of induction, weekly for three weeks, and post-induction and were compared over time using paired t-tests. GA was administered at baseline and post-induction, and correlated with biomarker levels using Spearman correlations. Survival was estimated using Kaplan-Meier and compared by categorized biomarker level using Wilcoxon tests. RESULTS: Biomarker levels were stable during induction, except for CRP and IL-6 sR. Declines in objectively measured physical function [Short Physical Performance Battery (SPPB); r = 0.71, p < 0.01] and increases in self-reported limitation in instrumental activities of daily living (r = 0.81, p < 0.01) were correlated with increased TNFα sR1. Declines in SPPB were correlated with increased CRP (r = -0.73, p < 0.01). Improvement in depression was correlated with increased IL-6 sR (r = -0.59 p = 0.02). Survival was shorter in those with baseline TNFα or CRP levels above the median (6.1 vs. 40.2 months and 5.5 vs. 27.6 months respectively, p = 0.04 for both). CONCLUSION: Among older adults with AML, the relationships between TNFα sR1, CRP, and IL-6 sR with change in physical and emotional health during treatment warrants further investigation.
OBJECTIVES: To investigate changes in inflammatory biomarkers during induction therapy for older adults with acute myeloid leukemia (AML) and their associations with geriatric assessment (GA) measures and outcomes. METHODS: This was a single institution ancillary study to a prospective observational study (N = 20 consecutive adults aged ≥60 with newly diagnosed AML who received induction chemotherapy). Biomarkers (Interleukin-6 [IL-6], IL-6 soluble receptor [IL-6 sR], tumor necrosis factor alpha [TNFα], TNFα soluble receptor 1 [TNFα sR1], interleukin-3 [IL-3], C-reactive protein [CRP]) were collected at start of induction, weekly for three weeks, and post-induction and were compared over time using paired t-tests. GA was administered at baseline and post-induction, and correlated with biomarker levels using Spearman correlations. Survival was estimated using Kaplan-Meier and compared by categorized biomarker level using Wilcoxon tests. RESULTS: Biomarker levels were stable during induction, except for CRP and IL-6 sR. Declines in objectively measured physical function [Short Physical Performance Battery (SPPB); r = 0.71, p < 0.01] and increases in self-reported limitation in instrumental activities of daily living (r = 0.81, p < 0.01) were correlated with increased TNFα sR1. Declines in SPPB were correlated with increased CRP (r = -0.73, p < 0.01). Improvement in depression was correlated with increased IL-6 sR (r = -0.59 p = 0.02). Survival was shorter in those with baseline TNFα or CRP levels above the median (6.1 vs. 40.2 months and 5.5 vs. 27.6 months respectively, p = 0.04 for both). CONCLUSION: Among older adults with AML, the relationships between TNFα sR1, CRP, and IL-6 sR with change in physical and emotional health during treatment warrants further investigation.
Authors: W H Ettinger; R Burns; S P Messier; W Applegate; W J Rejeski; T Morgan; S Shumaker; M J Berry; M O'Toole; J Monu; T Craven Journal: JAMA Date: 1997-01-01 Impact factor: 56.272
Authors: Heidi D Klepin; Ann M Geiger; Janet A Tooze; Stephen B Kritchevsky; Jeff D Williamson; Leslie R Ellis; Denise Levitan; Timothy S Pardee; Scott Isom; Bayard L Powell Journal: J Am Geriatr Soc Date: 2011-09-13 Impact factor: 5.562
Authors: Laura A Schaap; Saskia M F Pluijm; Dorly J H Deeg; Tamara B Harris; Stephen B Kritchevsky; Anne B Newman; Lisa H Colbert; Marco Pahor; Susan M Rubin; Frances A Tylavsky; Marjolein Visser Journal: J Gerontol A Biol Sci Med Sci Date: 2009-07-21 Impact factor: 6.053
Authors: Abbas H Panju; Ali Danesh; Mark D Minden; David J Kelvin; Shabbir M H Alibhai Journal: Support Care Cancer Date: 2008-10-18 Impact factor: 3.603
Authors: Y T Cheung; T Ng; M Shwe; H K Ho; K M Foo; M T Cham; J A Lee; G Fan; Y P Tan; W S Yong; P Madhukumar; S K Loo; S F Ang; M Wong; W Y Chay; W S Ooi; R A Dent; Y S Yap; R Ng; A Chan Journal: Ann Oncol Date: 2015-04-28 Impact factor: 32.976
Authors: Kah Poh Loh; Chandrika Sanapala; Michelle Janelsins; Heidi D Klepin; Rebecca Schnall; Eva Culakova; Michael B Sohn; Paula Vertino; Martha Susiarjo; Marielle Jensen-Battaglia; Michael W Becker; Jane Liesveld; Jason H Mendler; Eric Huselton; Po-Ju Lin; Karen Mustian Journal: J Geriatr Oncol Date: 2021-12-21 Impact factor: 3.929
Authors: Richard J Lin; Colette N Owens; Esther Drill; Augustine Iannotta; Mayan Oliveros; Dylan L Schick; Ariela Noy; John F Gerecitano; Pamela R Drullinsky; Philip C Caron; Anita Kumar; Matthew J Matasar; Craig Moskowitz; Beatriz Korc-Grodzicki; Andrew D Zelenetz; Gilles A Salles; Paul A Hamlin Journal: Haematologica Date: 2022-05-01 Impact factor: 11.047
Authors: Kah Poh Loh; Chandrika Sanapala; Erin Elizabeth Watson; Marielle Jensen-Battaglia; Michelle C Janelsins; Heidi D Klepin; Rebecca Schnall; Eva Culakova; Paula Vertino; Martha Susiarjo; Po-Ju Lin; Jason H Mendler; Jane L Liesveld; Eric J Huselton; Kathryn Taberner; Supriya G Mohile; Karen Mustian Journal: Blood Adv Date: 2022-07-12